

PDA Journal of Pharmaceutical Science and Technology



Farewell and Thanks!

Kurt Brorson, Beth Junker, Antonio Moreira, et al.

PDA J Pharm Sci and Tech **2018**, 72 222

Access the most recent version at doi:[10.5731/pdajpst.2018.001107](https://doi.org/10.5731/pdajpst.2018.001107)

*EDITOR'S NOTE***Farewell and Thanks!**

This will be the final editorial from the present team. After almost a decade, PDA is taking the editorial responsibilities over with an internal team. We offer our thoughts and shared experiences below.

Kurt Brorson: It has been a great privilege to serve in the capacity of associate editor of the *PDA Journal*. It was an opportunity to learn not only the latest in biotech, but also about areas like formulation, small-molecule active pharmaceutical ingredients, and delivery devices outside of my main scientific area of focus. It is a key journal in the interface between industry and academia, and it also tackles regulatory issues. Very few other journals attempt this, and I'm glad to have been part of the effort for the past eight years. Best wishes for the next editorial team!

Beth Junker: As the most recent addition to the editorial team, I was only able to contribute to the journal as an associate editor for a few years. It was an overwhelmingly positive experience to work closely with the rest of the editorial team to facilitate publication of thought-provoking research in the area of regulatory science. Whether submittals were from industrial, academic, or government entities—or a combination thereof—the research topics were always timely and impactful. My best wishes for the new editors and staff in maintaining and improving this useful communication channel for the latest advances in regulatory science.

Tony Moreira: It has been a privilege and an honor to serve for nearly ten years as an associate editor for the *PDA Journal of Science and Technology*. The *Journal* occupies a unique position in connecting the bio/pharma industry with academia while interfacing as well with the regulatory side of the house. It was a great personal learning opportunity in which I was amazed with the diversity of topics that our industry covers and the scientific depth of the field. Equally impressive to me was the global source of the articles submitted for publication. I also wish to thank my colleagues on the editorial team for the knowledge they shared and the guidance they were always happy to provide. All the best wishes to the new team, and I

will look forward to continuing to benefit from the valuable resource the *Journal* will provide.

Anurag S. Rathore: After nearly 8 years of serving as an associate editor of the *PDA J Sci Technol*, it is time to bid adieu. Over the years, we saw the rise in readership of the *Journal*, and for me it was interesting to see how the *Journal* connects to the tens of thousands of academicians and industry professionals of the pharmaceutical industry. Indeed the *Journal* plays and will continue to play a key role towards ensuring growth of the PDA. Wishing the new editorial team all the best.

Mia Ricci: It's been a wonderful 8 years supporting the editorial team of the *Journal* and serving the PDA community. Thank you to all our readers, authors, reviewers, and editors. Please continue your support and dedication to the *Journal!*

Govind Rao: It has been a privilege working with this team and pushing the boundaries of regulatory science. Regulatory science is different from traditional science in that it requires an unusual perspective of trying to understand what could go wrong and the steps that need to be taken to prevent that. We have worked hard to create a system of rapid and fair peer review and hope that our community has benefited. Proudest moment: Finding out that our annual access is close to a million views! We wanted to make a difference, and it appears that people are reading the *Journal* in increasing numbers. Biggest surprise: Learning that glass can delaminate and end up in parenteral products—this is the kind of information that the focus on regulatory science provides.

We leave you with a sense of accomplishment and with our very best wishes for the incoming team and for a long and productive life for the *Journal*.

Thank you.
The PDA Journal Editorial Team

*Kurt Brorson, Beth Junker, Antonio Moreira,
Anurag Rathore, Mia Ricci, and Govind Rao**

* Corresponding Author:

Govind Rao, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250,
e-mail: grao@umbc.edu

doi: 10.5731/pdajpst.2018.001107

PDA Journal of Pharmaceutical Science and Technology



An Authorized User of the electronic PDA Journal of Pharmaceutical Science and Technology (the PDA Journal) is a PDA Member in good standing. Authorized Users are permitted to do the following:

- Search and view the content of the PDA Journal
- Download a single article for the individual use of an Authorized User
- Assemble and distribute links that point to the PDA Journal
- Print individual articles from the PDA Journal for the individual use of an Authorized User
- Make a reasonable number of photocopies of a printed article for the individual use of an Authorized User or for the use by or distribution to other Authorized Users

Authorized Users are not permitted to do the following:

- Except as mentioned above, allow anyone other than an Authorized User to use or access the PDA Journal
- Display or otherwise make any information from the PDA Journal available to anyone other than an Authorized User
- Post articles from the PDA Journal on Web sites, either available on the Internet or an Intranet, or in any form of online publications
- Transmit electronically, via e-mail or any other file transfer protocols, any portion of the PDA Journal
- Create a searchable archive of any portion of the PDA Journal
- Use robots or intelligent agents to access, search and/or systematically download any portion of the PDA Journal
- Sell, re-sell, rent, lease, license, sublicense, assign or otherwise transfer the use of the PDA Journal or its content
- Use or copy the PDA Journal for document delivery, fee-for-service use, or bulk reproduction or distribution of materials in any form, or any substantially similar commercial purpose
- Alter, modify, repackage or adapt any portion of the PDA Journal
- Make any edits or derivative works with respect to any portion of the PDA Journal including any text or graphics
- Delete or remove in any form or format, including on a printed article or photocopy, any copyright information or notice contained in the PDA Journal